Traders assign a 95.5% probability that no new COVID variant of concern will be declared before 2027 because current Omicron sublineages such as XFG and its descendants dominate circulation without meeting WHO or ECDC criteria for elevated transmissibility, immune escape, or severity. Surveillance data through mid-2026 show no rapid replacement events or public-health signals, with variants under monitoring like BA.3.2 remaining at low U.S. prevalence and co-circulating rather than surging. Ongoing genomic monitoring, updated 2026-2027 vaccines matched to prevalent strains, and reduced overall case volumes further support the consensus that thresholds for a new designation are unlikely to be crossed in the remaining months of 2026. A late-year emergence of a highly divergent lineage with clear clinical impact could still shift odds, though recent patterns make this improbable.